These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37304303)

  • 1. PD-1 inhibitors-based second-line therapy for metastatic gastric cancer.
    Gou M; Zhang Y; Wang Z; Dai G
    Front Immunol; 2023; 14():1136437. PubMed ID: 37304303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M; Zhang Y; Wang Z; Qian N; Dai G
    Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study.
    Duan Y; Li J; Zhou S; Bi F
    Front Immunol; 2024; 15():1370860. PubMed ID: 38933261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy.
    Gou M; Zhang Y; Liu T; Qu T; Si H; Wang Z; Yan H; Qian N; Dai G
    Front Oncol; 2021; 11():655716. PubMed ID: 34211839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 6. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
    Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
    [No Abstract]   [Full Text] [Related]  

  • 7. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
    Wang J; He Y; Zhang B; Lv H; Nie C; Chen B; Xu W; Zhao J; Cheng X; Li Q; Tu S; Chen X
    Front Oncol; 2022; 12():924149. PubMed ID: 35719979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
    Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
    J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study.
    Cheng M; Wang H; Zhao Y; Li G
    Drug Des Devel Ther; 2022; 16():887-897. PubMed ID: 35378925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
    Goldinger SM; Buder-Bakhaya K; Lo SN; Forschner A; McKean M; Zimmer L; Khoo C; Dummer R; Eroglu Z; Buchbinder EI; Ascierto PA; Gutzmer R; Rozeman EA; Hoeller C; Johnson DB; Gesierich A; Kölblinger P; Bennannoune N; Cohen JV; Kähler KC; Wilson MA; Cebon J; Atkinson V; Smith JL; Michielin O; Long GV; Hassel JC; Weide B; Haydu LE; Schadendorf D; McArthur G; Ott PA; Blank C; Robert C; Sullivan R; Hauschild A; Carlino MS; Garbe C; Davies MA; Menzies AM
    Eur J Cancer; 2022 Feb; 162():22-33. PubMed ID: 34952480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
    Zhang X; Zhou Y; Chen H; Chen C; Lin Z; He LN; Du W; Chen T; Hong S; Fu S
    Front Immunol; 2022; 13():1015444. PubMed ID: 36248788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
    Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
    Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
    Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study.
    Nie C; Xu W; Lv H; Gao X; Li G; Chen B; Wang J; Liu Y; Zhao J; He Y; Wang S; Chen X
    Front Pharmacol; 2022; 13():1043217. PubMed ID: 36467052
    [No Abstract]   [Full Text] [Related]  

  • 18. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
    Li LH; Chen WC; Wu G
    Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of immunotherapy rechallenge in advanced gastric cancer].
    Zhang XX; Yang XF; Li S; Wu C; Hou XF
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):605-612. PubMed ID: 37462017
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials.
    Zhang F; Liu Z; Liang J; Zhang F; Wu K; Zhou C; Lu Y; Wang X
    Clin Transl Oncol; 2020 Oct; 22(10):1750-1761. PubMed ID: 32086783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.